In vivo efficacy of SM-20302, a GP IIb/IIIa receptor anatagonist, correlates with ex vivo platelet inhibition in heparinized blood but not in citrated blood

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 6, 1998, Pages 954-960

  Rebello, Sam S ^a   Huang, Jinbao ^a   Saito, Kumi ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antiplatelet agent; GP IIb IIIa receptor antagonist; Platelets; Thrombosis

Indexed keywords

3 [3 (4 AMIDINOBENZAMIDO)PROPIONAMIDO] 2 (4 ETHYLBENZENESULFONAMIDO)PROPIONIC ACID; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CAROTID ARTERY THROMBOSIS; DOG; DRUG EFFICACY; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 0031744905     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.6.954     Document Type: Article

References (20)

1. Lefkovitz J, Plow EF, Topol EJ. Platelet glycoprotein Hb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
2. Mickelson JK, Simpson PJ, Lucchesi BR. Antiplatelet monoclonal F(ab′)2 antibody directed against the platelet GPIIb/IIIa receptor complex prevents coronary artery thrombosis in the canine heart. J Mol Cell Cardiol. 1989;21:393-405.
3. 2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation. 1990;81:617-627.
4. 2] prevents arterial but not venous rethrombosis. J Cardiovasc Pharmacol. 1995;26:241-250.
5. The EPIC Investigators. Evaluation of a chimeric monoclonal antibody c7E3 Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor for preventing ischemic complications of high-risk angioplasty. N Engl J Med. 1994;330:956-961.
6. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT (EPIC Investigators). Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis. Lancet. 1994;343:881-886.
7. White JG. Effects of ethylenediamine tetracetic acid (EDTA) on platelet structure. Scand J Haematol. 1968;5:241-254.
8. Pidard D, Didry D, Kunicki TJ, Nurden AT. Temperature-dependent effects of EDTA on the membrane glycoprotein IIb-IIIa complex and platelet aggregability. Blood. 1986;67:604-611.
9. Shattill SJ, Brass LF, Benett JS, Pandhi P. Biochemical and functional consequences of dissociation of the platelet membrane glycoprotein IIb-IIIa complex. Blood. 1985;66:92-98.
10. Fujimura K, Philips DR. Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes. J Biol Chem. 1983;258:10247-10252.
11. +2-dependent binding of a synthetic Arg-Gly-Asp (RGD) peptide to a single site on the purified platelet glycoprotein IIb-IIIa complex. J Biol Chem. 1989;264:13102-13108.
12. Dandona P, Thusu K, Khurana U, Love J, Aljada A, Mousa S. Calcium, calmodulin and protein kinase C dependence of platelet shape change. Thromb Res. 1996;81:163-175.
13. Lanza F, Stierle A, Gachet C, Cazenave JP. Differential effects of extra-and intracellular calcium chelation on human platelet function and glycoprotein IIb/IIIa complex stability. Nouv Rev Fr Hematol. 1992;34:123-131.
14. Heidenreich R, Eisman R, Surrey S, Delgrasso K, Bennett JS, Schwartz E, Poncz M. The organization of the gene for platelet glycoprotein IIb. Biochemistry. 1990;29:1232-1244.
15. Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol. 1990;6:329-357.
16. Rebello SS, Driscoll EM, Lucchesi BR. TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke. 1997;28:1789-1796.
17. Sakurama T, Horisawa S, Kurata H, Kishimoto H, Nakano M, Fukuoka T, Kohda A, Kaneko M. SM-20302, a novel GPIIb/IIIa antagonist, has shown a selective antithrombotic activity without increasing the risk of hemorrhage in vivo. Thromb Haemost. 1997;77(suppl):7. Abstract.
18. Rote WE, Davis JH, Mousa SA, Reilly TM, Lucchesi BR. Antithrombotic effects of DMP-728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovasc Pharmacol. 1994;23:681-689.
19. Rote WE, Nedelman MA, Mu DX, Manley PJ, Weisman H, Cunningham MR, Lucchesi BR. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys. Stroke. 1994;25:1223-1233.
20. Rote WE, Werns SW, Davis JH, Feigen LP, Kilgore KS, Lucchesi BR. Platelet GPIIb/IIIa receptor inhibition by SC-49992 prevents thrombosis and rethrombosis in the canine carotid artery. Cardiovasc Res. 1993;27:500-507.